This study was undertaken to characterize predictors of response to double nucleoside combinations among 245 human immunodeficiency virus -infected persons initiating antiretroviral therapy. The median time for receiving antiretroviral therapy in this group was 6 months, and the plasma virus load was 58,000 copies/mL. The most commonly prescribed regimens were zidovudine/lamivudine (154 subjects, 63%) and stavudine/lamivudine (46 subjects, 19%). A total of 96 (39%) subjects had their virus load decrease to õ500 copies/mL after the initiation of therapy. Of the 245 study subjects, 102 (41.6%) had §5 months of follow-up and two or more consecutive virus load determinations performed after the start of antiretroviral therapy. Multivariate analysis demonstrated that baseline virus load was the only significant factor associated with obtaining two or more plasma virus loads of õ500 copies/mL. Overall, these data demonstrate that dual nucleoside therapy (using currently licensed agents) cannot reliably achieve a high level of suppression of plasma virus load.
and decreased death rates [2] . However, this approach carries and stavudine, were available during the study period.
with it substantial quality of life and cost implications [3] . In A physician enrolling an HIV-positive person into the Centre's contrast, dual nucleoside therapy is proven to be clinically HIV/AIDS Drug Treatment Program must complete a drug request effective, less onerous to take, and less expensive [4 -7] . Deenrollment form. The enrollment request form acts as a legal prespite the natural attractiveness of these regimens, it has been scription and compiles information on the HIV-positive applicant's argued that widespread use of double nucleoside therapy will address, enrolling physician, HIV-specific drug history, CD4 cell promote the development of resistance as a result of its limited counts, current drug request, and plasma virus load. Each request ability to suppress viral replication. It would be desirable, is reviewed by the Centre's consultants to ensure that it meets the therefore, to identify a group of patients who could have Centre's established therapeutic guidelines [8] . be found for dual nucleoside regimens in an era of plasma [9] . The diagnosis of AIDS is defined according to the 1987 CDC virus load -driven antiretroviral therapy.
revised case definition, without incorporating CD4 cell counts [10] .
The Centre distributes antiretroviral drugs based on specific guidelines generated by the Centre's Therapeutic Guidelines Committee. In June 1996, the Centre adopted plasma virus load-driven JID 1998;178 (September) Dual Nucleoside Therapy roviral drugs was recommended. Plasma virus load was measured (79,000 vs. 53,500 copies/mL; P Å .080). We also observed a were a decrease in plasma virus load to levels õ5000 and 500 difference in the percentage of subjects in these regimens ever copies/mL at any time during the study period. In study subjects reaching a plasma virus load threshold of õ500 copies/mL or with more than one posttherapy virus load determination, we exama median log drop in plasma virus load over the study period.
ined two consecutive decreases in plasma virus loads to levels
The median log drop in plasma virus load was follow-up plasma virus loads after switching to triple-drug therwas used to identify baseline predictors of the suppression of viral apy, the median virus load at follow-up was 1100 copies/mL replication to õ500 or 5000 copies/mL. All reported P values are (interquartile range Å õ500 -11,000), and 35% had virus loads two-sided.
of õ500 copies/mL. Table 1 compares baseline demographic and clinical characteristics of persons who had their plasma virus loads suppressed Results to õ5000 copies/mL with those who did not. Plasma virus load decreased õ5000 copies/mL after the initiation of therapy A total of 306 persons in British Columbia were first prescribed combination antiretroviral therapy between 1 June 1996 in 181 (74%) subjects. Participants who had a decrease to õ5000 copies/mL had significantly lower median baseline and 28 February 1997. We excluded 61 subjects from this analysis because they did not have the required minimum of plasma virus loads (47,000 vs. 90,000 copies/mL; P õ .001), higher CD4 cell counts (0.350 vs. 0.270 1 10 9 cells/L; P Å two virus load determinations. The total study sample was the remaining 245 subjects. The overall median time receiving .014), and less frequent prior AIDS diagnoses (4.4% vs. 14.1%; P Å .018). The proportion of subjects with plasma virus load antiretroviral therapy for this group was 6.0 months (interquartile range Å 4.5 -7.6). No subjects were lost to follow-up decreasing to õ5000 copies/mL did not differ with respect to gender (P Å .872) or age (P Å .527). in this analysis.
In comparison to study participants, the 61 persons excluded Table 2 compares baseline demographic and clinical characteristics of persons whose plasma virus loads were supfrom this analysis were more likely to be women (25% vs. 13%; P Å .033). However, there was no difference between pressed to õ500 copies/mL and those whose were not. Plasma virus loads decreased to õ500 copies/mL after the initiation these 2 groups at baseline with respect to age (P Å .468), diagnosis of AIDS (P Å .782), plasma virus load (P Å .204), of therapy in 96 (39%) subjects. Similar to persons whose virus loads decreased to õ5000 copies/mL, those whose loads and CD4 cell count (P Å .441).
Median plasma virus load for the 245 study subjects at entry declined to õ500 copies/mL had significantly lower median baseline plasma virus loads (31,500 vs. 73,000 copies/mL, was 58,000 copies/mL (interquartile range Å 25,000 -97,000 copies/mL). There was no statistical difference at entry in P õ .001) and higher CD4 cell counts (0.360 vs. 0.315 cells 1 10 9 /L; P Å .019). The groups did not differ with respect plasma virus load by age (P Å .564). Subjects who had AIDS at baseline did not have significantly higher median plasma to age (P Å .086), gender (P Å .682), or prior AIDS diagnosis (P Å .392). virus loads at entry than those without a diagnosis of AIDS / 9d50$$se18 07-02-98 00:10:55 jinfa UC: J Infect Of the 245 study subjects, 102 (41.6%) had §5 months of baseline plasma virus load. As noted in the top panel, Ç70% -90% of the 124 subjects with baseline plasma virus loads of follow-up and two or more consecutive virus load determinations performed after the start of antiretroviral therapy. Data õ60,000 copies/mL ever had their plasma virus loads suppressed to õ5000 copies/mL. As shown in the lower panel, for these persons were analyzed to identify baseline characteristics of subjects who had at least two plasma virus loads of 60% -90% of the 52 participants with baseline plasma virus loads of õ60,000 copies/mL had at least two plasma virus õ5000 copies/mL and 500 copies/mL, respectively. Participants who had two or more plasma virus loads of õ5000 were loads of õ5000 copies/mL. Figure 2 shows the percentages of participants who had their significantly older (median age, 38 vs. 35 years; P Å .042) and had lower median plasma virus loads (37,000 vs. 91,000 copies/ plasma virus loads decrease to õ500 copies/mL while they were receiving two-drug therapy. As shown in the upper panel, mL; P õ .001) than those who did not. There was no significant difference in CD4 cell counts (P Å .560), gender (P Å .156), the 45 subjects with baseline plasma virus loads of 5000 -20,000 copies/mL had their plasma virus loads suppressed to or AIDS diagnoses (P Å .134) between the 2 groups. Subjects with plasma virus loads that decreased to õ500 copies/mL on õ500 copies/mL at least once in 66.7% of cases. However, the lower panel shows that only 31.3% of the 16 subjects with two or more occasions had significantly lower plasma virus loads at baseline (23,000 vs. 69,000 copies/mL; P .005) but plasma virus loads of õ20,000 copies/mL at baseline had at least two plasma virus loads of õ500 copies/mL. did not differ with respect to age (P Å .407), gender (P Å .649), baseline CD4 cell count (P Å .554), or prior AIDS In a multivariate model, adjusting for baseline CD4 cell counts, AIDS diagnoses, gender, and age, each log decrease diagnosis (P Å .592). Figure 1 displays the percentages of participants whose in baseline virus load was associated with a 7-fold increase (odds ratio, 7.00; 95% confidence interval, 3.36, 14.58; P õ plasma virus loads decreased to õ5000 copies/mL while they were receiving two-drug antiretroviral therapy, stratified by .001) in the likelihood of suppressing virus load to õ500 cop-/ 9d50$$se18 07-02-98 00:10:55 jinfa UC: J Infect ies/mL at least once while on double-drug combination therapy. Discussion Baseline virus load remained the only significant factor associOur results demonstrate that plasma virus load suppression ated with patients having two or more plasma virus loads of to õ5000 copies/mL occurred in 74% of antiretroviral naive õ500 copies/mL after starting double-drug combination therpersons. However, this declined to 56% when suppression to apy. õ5000 copies/mL twice was considered. Furthermore, only Further analyses were completed to determine differences in 39% of participants had their plasma virus load decrease to disease progression among subjects who did and did not have õ500 copies/mL, and merely 13% had this level of suppression at least one virus titer of õ500 copies/mL. Over the 5-month maintained for two or more virus load measurements. Only study period, we observed no difference between these 2 groups baseline plasma virus load remained statistically significant in with respect to the subsequent percent change in CD4 cell univariate and multivariate analyses as the criteria for supprescount (P Å .297), progression to AIDS (P Å .399), or death sion became more stringent. However, 68.8% of subjects with (P Å .770). The median increase in CD4 cell count was 28% baseline plasma virus loads of 5000 -20,000 copies/mL did not in subjects with at least one virus titer of õ500 copies/mL and have plasma virus loads of õ500 copies/mL twice in our study. 22% in participants whose counts never reached this threshold. One case of AIDS was observed among 91 AIDS-free subjects While previous treatment recommendations suggested that 5000 copies/mL was an adequate goal for antiretroviral therapy who had at least one virus load determination of õ500 copies/ mL. There were no new AIDS cases observed among the 197 [1] , an international consensus has emerged in favor of higher levels of suppression of plasma virus load [3] . In the context AIDS-free persons whose counts did not reach this threshold. Finally, 2 deaths occurred among study subjects (one in each of previous guidelines (contemporary to this study), dual nucleoside therapy could have been considered a reasonable option virus titer grouping). Figure 1 . Top, % of participants with plasma virus load ever dropping to õ5000 copies/mL. (n Å 245). Bottom, % of participants having §2 plasma virus loads of õ5000 copies/mL (n Å 102).
for persons with low baseline virus loads of õ20,000 copies/ suppression of their plasma virus loads with dual nucleoside therapy, we cannot reliably identify them; consequently, we mL, and perhaps even for those with loads of õ60,000 copies/ mL. However, if the most recent guidelines are followed, dual place the majority of patients in this group at risk for early failure of a two-nucleoside regimen. In an era in which the nucleoside therapy ceases to be a viable option because it fails to meet its objective in the vast majority of patients [13] . management of HIV infection is aimed to provide long-term suppressive therapy with a limited number of agents, using Our data demonstrate that there are no reliable predictors of response to dual nucleoside therapy. While a lower baseline two nucleoside analogues represents an undesirable strategy because it will predictably fail to adequately suppress plasma plasma virus load is significantly associated with a higher rate of suppression of plasma virus load, it fails to reliably identify virus load and, in turn, jeopardize future treatment options.
Rates of disease progression among subjects who did and a group of patients who will fully respond to dual nucleoside therapy. Only 13% of subjects showed sustained suppression did not have at least one virus titer of õ500 copies/mL were not statistically different in our study. This is not unexpected, of plasma virus load to õ500 copies/mL, and this response correlated poorly with baseline plasma virus load. In other considering the limited follow-up time and low rates of mortality and AIDS incidence for those on double therapy, as already words, although close to one-third of patients with low baseline plasma virus loads (õ20,000 copies/mL) can have a sustained documented in this population-based cohort [14] . Furthermore, / 9d50$$se18 07-02-98 00:10:55 jinfa UC: J Infect Figure 2 . Top, % of participants with plasma virus load ever dropping to õ500 copies/mL (n Å 245). Bottom, % of participants having §2 plasma virus loads of õ500 copies/mL (n Å 102).
study participants who do not have viral suppression to õ500 sons. This is consistent with the revised guidelines of the International AIDS Society -USA [1] . copies/mL and those demonstrating rebound in viral replication despite continued therapy were offered a change to a new tripleSeveral features of our study should be emphasized. Our study was carried out within a provincewide treatment program, drug regimen, as recommended by contemporary guidelines [1, 8] . This would further delay the accrual of clinical end points in which all persons had access to combination antiretroviral therapy laboratory monitoring and medical care free of cost. in this cohort.
Although definitive evidence regarding the relative efficacy Our results, therefore, are not influenced by access-to-care issues, which have often compromised the interpretation of simiof various treatment strategies can be gathered only in the context of randomized clinical trials, this study provides imlar population-based studies. No subject was lost to follow-up as a result of the centralization of antiretroviral drug distribuportant confirmatory evidence regarding the effect of dual nucleoside therapy on plasma virus load. These results have led tion in our program, which thus compares favorably with other observational studies of this nature [15] . to the revision of our therapeutic guidelines, in favor of tripledrug therapy, including two nucleosides plus either a potent In summary, our data demonstrate that only a small minority of patients receiving dual nucleoside therapy can have their protease inhibitor (such as indinavir or ritonavir or possibly nelfinavir) or a nonnucleoside reverse transcriptase inhibitor plasma virus loads suppressed to acceptable levels and only a fraction of those can have this level of suppression maintained (such as nevirapine) as first-line therapy for HIV-infected per-/ 9d50$$se18 07-02-98 00:10:55 jinfa UC: J Infect
